Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

804
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
804
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

1.3K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.3K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SECmeres outperform extracellular vesicles as potential blood RNA biomarkers for Alzheimer's disease.

Nature communications·2026
Same author

The Proteo-Transcriptome of Extracellular Vesicles and Particles Is Largely Preserved After Cryopreservation.

Journal of extracellular biology·2026
Same author

Gene regulatory programs of cognitive resilience and pathogenesis in Alzheimer's disease.

medRxiv : the preprint server for health sciences·2026
Same author

Dynamic Alterations in the Blood Transcriptome Characterize Drug Use Behavior and Co-Morbidities in Cocaine Use Disorder: A Preliminary Study.

The European journal of neuroscience·2026
Same author

Several novel classes of small regulatory RNAs show widespread changes in schizophrenia and bipolar disorder and extensive linkages to critical brain processes.

Translational psychiatry·2026
Same author

Single-cell atlas of transcriptomic vulnerability across multiple neurodegenerative and neuropsychiatric diseases.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Mar 19, 2026

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

9.0K

The relationship between dopamine receptor D1 and cognitive performance.

Jonathan Tsang1, John F Fullard2, Stella G Giakoumaki3

  • 1Icahn School of Medicine at Mount Sinai , New York, NY, USA.

NPJ Schizophrenia
|June 24, 2016
PubMed
Summary

Genetic variations in the dopamine receptor D1 (DRD1) gene are linked to cognitive impairment. This study reveals a potential mechanism connecting DRD1 to cognitive performance changes.

More Related Videos

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

26.6K

Related Experiment Videos

Last Updated: Mar 19, 2026

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

9.0K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

26.6K

Area of Science:

  • Neuroscience
  • Genetics
  • Psychiatry

Background:

  • Cognitive impairment is a common symptom across various psychiatric and neurobiological disorders.
  • Understanding the genetic basis of cognitive function is crucial for developing targeted treatments.

Purpose of the Study:

  • To investigate the genetic association between 94 candidate genes involved in neurotransmission and cognitive measures.
  • To explore the role of specific genetic variations in cognitive performance and related molecular mechanisms.

Main Methods:

  • Utilized a large postmortem cohort (n=727) with Alzheimer's disease, schizophrenia, and controls, measuring cognition using the Clinical Dementia Rating (CDR).
  • Genotyped single-nucleotide polymorphisms (SNPs) in 94 genes using a custom array and performed targeted SNP genotyping in a healthy cohort (n=1,493).
  • Quantified gene expression in the superior temporal gyrus and assessed transcriptional activity using a luciferase reporter system.

Main Results:

  • The rs5326-A allele in the dopamine receptor D1 (DRD1) promoter region was significantly associated with poorer cognition (higher CDR) in the postmortem cohort (P=9.325×10(-4)).
  • This allele also correlated with worse strategic planning performance in the LOGOS cohort (P=0.008).
  • Lower DRD1 gene expression (P=0.038) and decreased transcriptional activity (P=0.026) were observed in relevant cellular models.

Conclusions:

  • The study identified a significant genetic association between DRD1 and cognitive performance.
  • Findings suggest a mechanistic link between DRD1 variations, gene expression, transcriptional activity, and cognitive alterations.
  • An interdisciplinary approach integrating genetics, cognitive, and molecular neuroscience provides insights into the neurobiological underpinnings of cognitive function.